Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Upper GI Disease on Oral Semaglutide PK in T2D
NCT02877355Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2016
- Primary completion
- Nov 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Area under the semaglutide plasma concentration-time curve. Started Aug 2016; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02877355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02877355.